EUVIMEDEUVIMED entdecken
Crossref

Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice

Miriam Potrony, Blai Morales-Romero, Lorena Moreno, Belen Pastor, Elia Grau, Celia Badenas, José Luis Villanueva-Cañas, Aina Montalbán-Casafont, Coral Arnau-Collell, Teresa Ramon Y Cajal, Isabel Aragón Manrique, Pilar Carrasco Salas und 15 weitere

Breast Cancer Research and Treatment · 2025-04 · 210 (3) · 507-519

DOI: 10.1007/s10549-025-07643-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 24.02.2025. Verfasst von Miriam Potrony und 26 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry and Molecular Genetics Department, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hereditary Breast and Ovarian Cancer Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The implementation of the next-generation sequencing (NGS) in clinical practice has improved the genetic diagnosis of Hereditary Breast and Ovarian Cancer Syndrome (HBOC). We aimed to evaluate the diagnostic outcomes of using an NGS cancer gene panel in clinical practice for patients selected based on personal and/or family history of breast, ovarian, prostate, melanoma, and other HBOC-associated cancers. METHODS: The study series included 2561 consecutive Spanish individuals referred for genetic testing, comprising 2445 cancer patients and 116 healthy individuals with family history of HBOC. Eleven HBOC susceptibility genes (BRCA1, BRCA2, PALB2, ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D, TP53, and PTEN) and three Lynch Syndrome genes (MLH1, MSH2, and MSH6) available for opportunistic testing were analyzed using a commercial Hereditary Cancer Panel and an in-house bioinformatics pipeline. RESULTS: Overall, the diagnostic yield was 11.0% in cancer patients and 8.6% in healthy individuals with a family history of breast/ovarian cancer. Pathogenic variants in high-risk genes were more frequent in patients with multiple HBOC tumors and a family history of different HBOC cancers. Additionally, we diagnosed five families with Lynch syndrome through opportunistic testing. CONCLUSION: Testing cancer susceptibility genes using an agnostic strategy confers a diagnostic benefit for hereditary cancer syndromes compared to phenotype-driven test, without adding complexity to the study. The analysis of healthy individuals with a family history of HBOC detects pathogenic variants in a cost-efficient percentage of cases, resulting in a good alternative strategy when the index case is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hereditary Breast and Ovarian Cancer SyndromeHumansFemaleGenetic Predisposition to DiseaseMiddle AgedGenetic TestingAdultHigh-Throughput Nucleotide SequencingAgedMaleBiomarkers, TumorYoung AdultMutation

Stichwörter der Autor:innen

Breast cancerGenetic counselingGeneticsHereditary cancerNGSVariants

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Biochemistry and Molecular Genetics Department, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
  • Gastroenterology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Department of Medical Oncology, Institute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Molecular Biology CORE (CDB), Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.

Zitieren

APA

Potrony, M., Morales-Romero, B., Moreno, L., Pastor, B., Grau, E., Badenas, C., Villanueva-Cañas, J. L., Montalbán-Casafont, A., Arnau-Collell, C., Ramon Y Cajal, T., Aragón Manrique, I., Carrasco Salas, P., Puig, S., Aguilera, P., Alonso, I., Cebrecos, I., González-Bosquet, E., Mellado, B., Ferrer-Mileo, L., …, & Puig-Butillé, J. A. (2025). Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice. Breast Cancer Research and Treatment, 210(3), 507-519. https://doi.org/10.1007/s10549-025-07643-4

Vancouver

Potrony M, Morales-Romero B, Moreno L, Pastor B, Grau E, Badenas C, et al. Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice. Breast Cancer Research and Treatment. 2025;210(3):507-519. doi:10.1007/s10549-025-07643-4

BibTeX
@article{Potrony2025,
  author = {Potrony, Miriam and Morales-Romero, Blai and Moreno, Lorena and Pastor, Belen and Grau, Elia and Badenas, Celia and Villanueva-Cañas, José Luis and Montalbán-Casafont, Aina and Arnau-Collell, Coral and Ramon Y Cajal, Teresa and Aragón Manrique, Isabel and Carrasco Salas, Pilar and Puig, Susana and Aguilera, Paula and Alonso, Inmaculada and Cebrecos, Isaac and González-Bosquet, Eduardo and Mellado, Begoña and Ferrer-Mileo, Laura and Rodriguez-Hernandez, Adela and Prat, Aleix and Muñoz, Montserrat and Gaba, Lydia and Adamo, Barbara and Oriola, Josep and Sánchez, Aurora and Puig-Butillé, Joan Anton},
  title = {Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  volume = {210},
  number = {3},
  pages = {507--519},
  doi = {10.1007/s10549-025-07643-4}
}
Kostenlos starten →